Pharmacist - Open Access .click

Results 241 to 250 of about 364,595 (399)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source

Long-term trends in the labour supply and productivity of pharmacists in Canada. [PDF]

Can Pharm J (Ott)
Grootendorst P, Kralj B, Sweetman A.
europepmc +1 more source

The community pharmacist: health sentinel on the home front.

, 1974
P Gervasi
openalex +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source

Optimisation of lipid-lowering therapy post-Acute Coronary Syndromes: a multidisciplinary, cross-interface novel pharmacy care model within a local cardiac rehabilitation centre. [PDF]